• “We are confident that based on the mechanism of our vaccine, even though there are mutations, we believe that the immune response which is induced by our vaccine could also deal with (a) mutated virus,” Dr. Ugur Sahin, co-founder and CEO of BioNTech, told CNBC’s Meg Tirrell on Monday.
  • Public health experts have expressed concern the new mutant strains could pose a threat to inoculation efforts.
  • When asked how quickly BioNTech could pivot if it turned out the existing Covid vaccine was found to be ineffective against new variants, Sahin said “one key advantage” of the mRNA technology was that it would allow the company to adapt the vaccine “relatively quickly.”

Bill Oxford/iStock

Read more…